During the last session, Amylyx Pharmaceuticals Inc (NASDAQ:AMLX)’s traded shares were 2.09 million, with the beta value of the company hitting -0.60. At the end of the trading day, the stock’s price was $4.58, reflecting an intraday loss of -5.95% or -$0.29. The 52-week high for the AMLX share is $7.27, that puts it down -58.73 from that peak though still a striking 65.5% gain since the share price plummeted to a 52-week low of $1.58. The company’s market capitalization is $408.01M, and the average trade volume was 825.25K shares over the past three months.
Amylyx Pharmaceuticals Inc (AMLX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.50. AMLX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.51.
Amylyx Pharmaceuticals Inc (NASDAQ:AMLX) trade information
Amylyx Pharmaceuticals Inc (AMLX) registered a -5.95% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.95% in intraday trading to $4.58, hitting a weekly high. The stock’s 5-day price performance is -10.89%, and it has moved by 38.37% in 30 days. Based on these gigs, the overall price performance for the year is 130.15%.
The consensus price target of analysts on Wall Street is $10.5, which implies an increase of 56.38% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $10 and $11 respectively. As a result, AMLX is trading at a discount of -140.17% off the target high and -118.34% off the low.
Amylyx Pharmaceuticals Inc (AMLX) estimates and forecasts
In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled -1.02M and 416k respectively. In this case, analysts expect current quarter sales to grow by 100.00% and then drop by -100.00% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -78.71%. While earnings are projected to return 57.97% in 2025, the next five years will return 27.51% per annum.
AMLX Dividends
Amylyx Pharmaceuticals Inc is due to release its next quarterly earnings in June. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
The next largest institutional holding, with 3.34 million shares, is of AQR CAPITAL MANAGEMENT LLC’s that is approximately 4.9114% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $6.35 million.
Also, the Mutual Funds coming in first place with the largest holdings of Amylyx Pharmaceuticals Inc (AMLX) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and abrdn Healthcare Investors . Data provided on Dec 31, 2024 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 1.48 shares. This amounts to just over 1.66 percent of the company’s overall shares, with a $6.79 million market value. The same data shows that the other fund manager holds slightly less at 1.2, or about 1.34% of the stock, which is worth about $5.48 million.
